Net Cash Provided by (Used in) Financing Activities in USD of Theriva Biologics, Inc. from 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Theriva Biologics, Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2010 to Q1 2025.
  • Theriva Biologics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $3,072,000.
  • Theriva Biologics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $5,496,000, a 779% increase from 2023.
  • Theriva Biologics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $625,000.
  • Theriva Biologics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $1,930,000, a 103% decline from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Theriva Biologics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $3,072,000 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q1 2023 $55,000 +$1,321,000 +96% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q1 2022 $1,376,000 -$75,378,000 -102% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q1 2021 $74,002,000 +$74,002,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q1 2020 $0 $0 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q1 2019 $0 $0 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020 2020 Q1
Q1 2018 $0 -$435,000 -100% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q1 2017 $435,000 +$435,000 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q1 2016 $0 $0 01 Jan 2016 31 Mar 2016 10-Q 04 May 2017 2017 Q1
Q1 2015 $0 -$4,000 -100% 01 Jan 2015 31 Mar 2015 10-Q 11 May 2015 2015 Q1
Q1 2014 $4,000 -$227,000 -98% 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015 2015 Q1
Q1 2013 $231,000 -$1,308,000 -85% 01 Jan 2013 31 Mar 2013 10-Q 15 May 2013 2013 Q1
Q1 2012 $1,539,000 -$2,173,000 -59% 01 Jan 2012 31 Mar 2012 10-Q 15 May 2013 2013 Q1
Q1 2011 $3,712,000 01 Jan 2011 31 Mar 2011 10-Q 15 May 2012 2012 Q1

Theriva Biologics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $5,496,000 +$4,871,000 +779% 01 Jan 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
2023 $625,000 +$2,555,000 01 Jan 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
2022 $1,930,000 -$75,932,000 -103% 01 Jan 2022 31 Dec 2022 10-K 25 Mar 2024 2023 FY
2021 $74,002,000 +$70,643,000 +2103% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $3,359,000 +$3,359,000 01 Jan 2020 31 Dec 2020 10-K 16 Mar 2022 2021 FY
2019 $0 -$29,088,000 -100% 01 Jan 2019 31 Dec 2019 10-K 04 Mar 2021 2020 FY
2018 $29,088,000 +$10,611,000 +57% 01 Jan 2018 31 Dec 2018 10-K 20 Feb 2020 2019 FY
2017 $18,477,000 -$8,230,000 -31% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2019 2018 FY
2016 $26,707,000 -$15,977,000 -37% 01 Jan 2016 31 Dec 2016 10-K 22 Feb 2018 2017 FY
2015 $42,684,000 +$23,657,000 +124% 01 Jan 2015 31 Dec 2015 10-K 22 Feb 2018 2017 FY
2014 $19,027,000 +$6,601,000 +53% 01 Jan 2014 31 Dec 2014 10-K 02 Mar 2017 2016 FY
2013 $12,426,000 +$224,000 +1.8% 01 Jan 2013 31 Dec 2013 10-K 10 Mar 2016 2015 FY
2012 $12,202,000 +$5,223,000 +75% 01 Jan 2012 31 Dec 2012 10-K 16 Mar 2015 2014 FY
2011 $6,979,000 +$5,965,000 +588% 01 Jan 2011 31 Dec 2011 10-K 16 Apr 2013 2012 FY
2010 $1,014,000 01 Jan 2010 31 Dec 2010 10-K/A 11 May 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.